今すぐお試しください
プロフィール
Tempus is a technology company advancing precision medicine through AI-powered genomic analysis and clinical data integration. Founded in 2015 by Eric Lefkofsky, Tempus has built the world's largest library of molecular and clinical data, partnering with over 7,000 physicians and 65% of US academic medical centers. The platform combines next-generation sequencing with machine learning to provide personalized cancer treatment recommendations based on each patient's unique molecular profile.
What sets Tempus apart is its comprehensive approach to precision oncology, integrating genomic sequencing, clinical data analytics, and real-world evidence into a unified platform. Physicians order Tempus testing through a simple process - tumor and blood samples are sequenced using validated panels covering hundreds of cancer-related genes. Advanced AI algorithms analyze the molecular data alongside clinical information, treatment histories, and outcomes from thousands of similar patients to identify targeted therapies, immunotherapies, and clinical trials matching the patient's specific cancer profile.
Tempus serves oncologists, cancer patients, pharmaceutical companies, and research institutions. The platform has demonstrated clinical utility in guiding treatment decisions for solid tumors and hematologic malignancies, with studies showing improved patient outcomes when therapy is selected based on molecular profiling. With CLIA-certified laboratory operations, comprehensive bioinformatics pipelines, and continuous algorithm improvements from real-world data, Tempus represents the cutting edge of AI-driven personalized cancer care.
主な特長
Comprehensive Genomic Sequencing
Next-generation sequencing of 500+ cancer-related genes with high depth coverage. Detects mutations, copy number alterations, fusions, and other genomic biomarkers.
Clinical Data Analytics
AI-powered analysis integrating molecular data with clinical information, treatment history, and patient outcomes. Provides actionable insights for treatment planning.
Treatment Matching Algorithms
Machine learning identifies targeted therapies and immunotherapies most likely to benefit each patient. Matches molecular profile to approved drugs and investigational agents.
Clinical Trials Matching
Automated identification of relevant clinical trials based on genomic profile and eligibility criteria. Expands treatment options beyond standard therapies.
Molecular Profiling Reports
Comprehensive genomic reports with therapy recommendations, prognostic information, and biomarker status. Designed for clinical decision-making.
Therapy Recommendations
Evidence-based treatment suggestions ranked by likelihood of response. Includes FDA-approved options and off-label uses supported by clinical data.
Outcomes Tracking Platform
Longitudinal monitoring of treatment responses and disease progression. Real-world evidence collection to improve future recommendations.
Research and Discovery Tools
De-identified data access for pharmaceutical research and biomarker discovery. Supports drug development and precision oncology research.
長所と短所
Advantages
- Largest molecular and clinical database
- Comprehensive genomic panels
- AI-powered treatment matching
- Clinical trials identification
- CLIA-certified laboratory
- Rapid turnaround times
- Integration of real-world evidence
- Supports multiple cancer types
- Evidence-based recommendations
- Physician network of 7000+
Disadvantages
- Expensive testing (though often covered by insurance)
- Primarily focused on cancer
- Requires tumor tissue sample
- Not all mutations have actionable targets
- Complexity may overwhelm some physicians
- Limited pediatric oncology coverage
- Insurance authorization sometimes needed
- Interpretation requires oncology expertise
料金プラン
| Service | 価格 | Coverage | Best For |
|---|---|---|---|
| xT Sequencing | Variable | DNA + RNA, 500+ genes | Comprehensive solid tumor profiling |
| xF Sequencing | Variable | DNA, targeted genes | Focused genomic analysis |
| xR Sequencing | Variable | RNA expression | Gene expression profiling |
| Insurance Billing | $0 patient cost (typically) | Covered by most major insurers | Insured patients |
最高のユースケース
Tempus Excels At:
- Advanced Cancer Treatment Planning: Identifying personalized therapy options for metastatic and treatment-resistant cancers
- Targeted Therapy Selection: Matching patients to FDA-approved targeted agents based on specific mutations
- Immunotherapy Eligibility: Determining biomarkers like PD-L1, TMB, and MSI status for immunotherapy candidacy
- Clinical Trial Enrollment: Finding relevant trials when standard options are exhausted
- Precision Oncology Programs: Supporting institutional precision medicine initiatives
- Pharmaceutical Research: Real-world evidence generation and biomarker discovery
- Multi-Cancer Profiling: Applicable across solid tumors and hematologic malignancies
- Longitudinal Monitoring: Tracking genomic evolution and treatment resistance patterns
May Not Be Ideal For:
- Early-stage cancers with standard treatment protocols
- Patients without adequate tumor tissue for sequencing
- Non-oncology applications (platform is cancer-focused)
- Resource-limited settings without genomic expertise
How It Compares
Tempus vs Foundation Medicine
Both are leaders in cancer genomic profiling, but with different strengths. Tempus offers broader data integration with clinical outcomes and real-world evidence, while Foundation Medicine (Roche) provides deeply validated genomic testing with extensive pharmaceutical partnerships. Tempus's AI algorithms leverage a larger clinical database for treatment matching, while Foundation Medicine's FoundationOne CDx has FDA approval as a companion diagnostic for multiple drugs. Tempus may have advantages in clinical trials matching and outcomes data, while Foundation Medicine excels in regulatory validated testing for specific targeted therapies. Many cancer centers use both platforms for complementary insights.
Tempus vs Standard Cancer Treatment
Traditional oncology relies on cancer type, stage, and limited biomarkers to guide treatment decisions. Tempus provides comprehensive molecular profiling revealing hundreds of potential therapeutic targets and resistance mechanisms invisible to standard testing. Studies show genomic profiling identifies actionable mutations in 30-40% of patients, with 15-20% receiving treatments they wouldn't have otherwise. While not all patients benefit from genomic testing, those with rare cancers, treatment-resistant disease, or uncommon presentations often gain valuable therapeutic options. The integration of real-world outcomes data helps predict which treatments are most likely to work for each patient's specific molecular profile.
最終的な評決
推奨事項
Tempus represents a paradigm shift in cancer care, bringing the power of precision medicine and artificial intelligence to oncology practice. For patients with advanced or treatment-resistant cancers, Tempus genomic profiling can identify personalized treatment options that significantly improve outcomes. The platform's comprehensive integration of molecular data, clinical information, and real-world evidence provides oncologists with actionable insights for therapy selection. With partnerships across 65% of US academic medical centers and usage by over 7,000 physicians, Tempus has proven clinical utility and adoption. While genomic testing adds complexity and cost to cancer care, insurance coverage by major payers makes Tempus accessible to most patients when clinically indicated. The AI-powered treatment matching and clinical trials identification are particularly valuable when standard therapies fail or for rare cancer subtypes lacking established protocols. Tempus is most beneficial for patients with metastatic disease, multiple prior treatments, rare cancers, or when molecular biomarkers could guide therapy selection. The platform's continuous learning from real-world outcomes means recommendations improve over time as more data accumulates. For oncologists practicing precision medicine, Tempus provides comprehensive genomic analysis with clinical decision support that goes beyond raw sequencing data. The CLIA-certified laboratory and validated bioinformatics pipelines ensure test quality and reliability. If you're an oncologist seeking to incorporate precision medicine into practice, or a cancer patient exploring all treatment options, Tempus offers cutting-edge genomic analysis with actionable recommendations. While not every patient will benefit from genomic testing, those who do often gain access to life-extending therapies they wouldn't have otherwise received.
スクリーンショットとインターフェイス
Explore Tempus's interface:
